The only genomic test proven to predict a patient’s individual benefit from chemotherapy. For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit. The Breast Recurrence Score® assay is one of the most extensively studied genomic tests available for breast cancer patients today, with prospective clinical trials and outcome data gathered from more than 100,000 patients in more than 150 publications, providing the highest level of evidence supporting the test’s clinical utility. The Breast Recurrence Score test is the only validated genomic test for breast cancer, which provides two key answers for both lymph node-negative and node-positive early-stage breast cancer patients: ● The test predicts whether a woman will benefit from chemotherapy. ● It also provides a percent likelihood of the cancer returning after appropriate hormone therapy is taken.
read More
The only genomic test to quantify the risk of local recurrence (DCIS or invasive) in ductal carcinoma in situ. For patients with ductal carcinoma in situ (DCIS) treated by local excision, with or without tamoxifen, the Oncotype DX Breast DCIS Score can help guide personalized treatment decisions.
read More
A genomic test that quantifies the risk of recurrence, for insight beyond traditional measures. For patients with stage II or II A/B colon cancer whose tumor has been resected, the Oncotype DX Colon Recurrence score can help guide decisions about adjuvant treatment.
read More© Copyright 2022 - 24 | All Rights Reserved.
